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PCI
(n=560)
CABG
(n=280)
P
value
1-month outcomes
MACE (death, MI, revascularization) 13.4% 15.4% 0.46
NACE (death, MI, revascularization, and major
bleeding)
19.1% 17.5% 0.45
All-Cause Mortality 2.1% 3.6% 0.22
Myocardial Infarction 10.2% 12.7% 0.33
Unplanned Revascularization 4.3% 1.4% 0.03*
Stroke 0.2% 0.7% 0.26
1-year outcomes
MACE 22.4% 19.7% 0.49
Death or MI 15.4% 16.4% 0.65
All-Cause Mortality 4.3% 4.7% 0.72
MI 12.7% 13.1% 0.88
Unplanned Revascularization 12.7% 5.2% 0.001*
TLR 8.5% n/a
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experience no chest pain and are given a low priority score at the triage of emergency
department. We aimed to determine the impact of non-chest pain complaint
as a presenting symptom on the DTB time and clinical outcomes in patients with
STEMI.
Methods: A total of 11,417 STEMI patients who underwent primary PCI were
derived from the Korea Working Group on Myocardial Infarction from 2005 to 2012
and compared according to typical chest pain or non-chest pain complaint as a pre-
senting symptom. The primary outcomes were 12-month mortality and the composite
of major adverse cardiac events (MACE, deﬁned as death, non-fatal myocardial
infarction, and revascularization).
Results: Compared to patients with typical chest pain (n¼9,948, 87.1%), patients
with non-chest pain complaint (n¼1,469, 12.9%) were older, more female, and had
higher incidence of hypertension and diabetes, and also had higher incidence of
anterior infarct and higher Killip class. The time delay was also signiﬁcant in door-
to-laboratory arrival time (53 vs. 64 min, p<0.001), laboratory arrival-to-balloon
(20 vs. 23 min, p<0.001), and the DTB time (75 vs. 89 min, p<0.001). Non-chest
pain complaint was an independent determinant of the DTB time both in adjusted
models and in multivariate linear regression analysis. Patients with non-chest pain
complaint had more in-hospital death (4.1% vs. 11.5%, p<0.001), 12-month
mortality (6.5% vs. 16.3%, p<0.001), and the composite of MACE (12.2% vs.
22.5%, p<0.001).
Conclusions: The delays in identiﬁcation of STEMI and reperfusion treatment were
greater and associated with worse clinical outcomes in patients with non-chest pain
complaint as a presenting symptom. A triage using electrocardiogram should be
considered in these patients.Heparin + GPI
N=1532
Bivalirudin alone
N=1611 p value
30-days
Mortality 0.9% 1.5% 0.14
MI 5.8% 7.2% 0.0958
Urgent TVR 2.4% 2.1% 0.5720
NACE 13.5% 12.6% 0.4482
Composite ischemic outcome 8.2% 9.3% 0.3001
Non-CABG major bleeding 7.1% 4.1% 0.0002
1-year
Mortality 4.0% 3.8% 0.8293
Composite ischemic outcomes 17.4% 19.0% 0.0629TCT-260
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Background: Proximal LAD (pLAD) lesions are associated with increased cardio-
vascular risk in the setting of acute coronary syndrome (ACS). Surgical versus
percutaneous revascularization improves outcomes including mortality in complex
stable CAD. However, the impact of different revascularization strategies in ACS
patients with pLAD lesions remains unknown.
Methods: We performed a post-hoc analysis of patients in the ACUITY trial
(n¼13,819) presenting with a critical stenosis of the pLAD who underwent subse-
quent revascularization with a surgical or percutaneous approach (PCI). Major adverse
events comprised of death, myocardial infarction, repeat revascularization, stroke, and
bleeding were compared at 30 days and 1-year.
Results: Among the 842 patients we studied, revascularization was performed with
PCI and coronary artery bypass grafting (CABG) in n¼562 (67%) and n¼280 (33%)
respectively. Baseline clinical and angiographic characteristics were well balanced
between groups. Patients in the CABG group were more likely to undergo angiog-
raphy later than PCI (median time ﬁrst drug-angiography, 43 vs. 4 hours, P<0.01).
PCI was associated with an increase rate of revascularization at 1 month and 1 year,
without signiﬁcant difference in other clinical endpoints (Table 1).
Conclusions: Although surgical revascularization of proximal LAD during ACS
reduces further revascularization, it does not seem to improve the survival and MI
rates at 1-year compared with PCI.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-261
Safety and efﬁcacy of Bivalirudin monotherapy in patients with non-ST segment
elevation myocardial infarction undergoing PCI: Results from the ACUITY
Study
Cristiano F. Souza1, Roxana Mehran2, Ajay J. Kirtane3, Sorin Brener4,
Tom McAndrew1, Frederick Feit5, Gregg W. Stone6
1Cardiovascular Research Foundation, New York, NY, 2Mount Sinai Hospital, New
York, NY, 3Columbia University / Cardiovascular Research Foundation, New York,
NY, 4New York Methodist Hospital, Brooklyn, United States, 5NYU, New York, NY,
6Cardiovascular Research Foundation, NY, NY
Background: There are limited data on the effects of bivalirudin monotherapy
compared to standard antithrombotic therapy (heparin plus glycoprotein IIb/IIIa
inhibitor – GPI) on the outcomes of higher –risk acute coronary syndromes
(ACS) patients with positive biomarkers on admission. We examined the clin-
ical outcomes among positive biomarker patients undergoing percutaneous
coronary intervention (PCI) in the large-scale prospective, randomized ACUITY
trial.
Methods: The ACUITY trial was a multicenter, randomized trial assessing the
safety and efﬁcacy of bivalirudin alone or bivalirudin plus GPI vs. heparin plus
GPI among 13,819 patients with moderate and high-risk ACS, 7,789 of
whom underwent PCI. The in-hospital and 30-days primary endpoints were
composite ischemia (death, MI, or unplanned TVR for ischemia), Non-CABG
major bleeding, and net adverse clinical events (NACE¼composite ischemia or
major bleeding).
Results: A total of 4,728 PCI patients presented with a positive biomarker at the time
of admission. Of those, 1,532 were randomized to heparin plus GPI and 1,611 to
bivalirudin alone. There were no relevant baseline differences between treatment
groups regarding clinical proﬁle, TIMI risk score, antiplatelet medications and DES
use. Outcomes by treatment group at 30-days and 1-year are shown in the table. In
a multivariate model, use of bivalirudin was not a predictor of composite ischemic
outcomes up to one year (hazard ratio [95% CI]¼1.12 [0.97, 1.29], p¼0.1239), but
was associated with a reduction in major bleeding.acts/POSTER/STEMI/NSTEMI/ACS B85
LAD that wrapped
around the apex
(n=206)
LAD that terminated at
or before the apex
(n=147)
p-
value
Time from symptom
onset to ﬁrst device
(min)
146 [119, 200] 158 [127, 222] 0.05
Occlusion at proximal
LAD
48.3% 51.7% 0.53
Pre PCI TIMI ﬂow
grade 0 or 1
68.4% 74.8% 0.19
Final TIMI ﬂow grade
3
94.2% 89.8% 0.13
% infarct mass of LV
mass (%) at 30 days
17.1 [7.9, 24.5] 16.8 [7.2, 22.8] 0.30
LV end diastolic
volume (mL) at 30
days
181 [150, 213] 166 [142, 197] 0.05
LV end systolic
volume (mL) at 30
days
89 [68, 117] 81 [64, 105] 0.06
MACHFE 8.9% (18) 3.4% (5) 0.05
New onset of severe
heart failure
6.9% (14) 2.0% (3) 0.04
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within the ACUITY trial, bivalirudin monotherapy (compared with heparin + GPI)
was associated with similar risk of ischemic events and signiﬁcant reduction of major
bleeding at 30 days and 1 year in patients undergoing PCI.
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Background: The efﬁcacy and safety of drug-eluting stents in STEMI patients is still
controversial and implantation of a bare-metal stent (BMS) is commonly preferred in
this patient population. The COMFORTABLE AMI trial has recently shown that, in
STEMI patients, a Biolimus A9-eluting stent with biodegradable polymer (BES) is
more effective and safer compared to BMS after 2 years follow-up. The e-BioMatrix
registry has evaluated the long-term safety and efﬁcacy of BES in a large real-world
patient population including patients with ST elevation myocardial infarction
(STEMI), non-ST elevation myocardial infarction (NSTEMI) and stable ischemic
heart disease (SIHD).
Methods: A total number of 959 STEMI, 1810 NSTEMI and 2785 SIHD patients
were enrolled. The primary endpoint was MACE, deﬁned as a composite of
cardiac death, MI and clinically-indicated TVR at 12 months. Secondary
endpoints were MACE at 30 days, 6 months, 2, 3, and 5 years, ARC deﬁned stent
thrombosis and total revascularization rates at 30 days, 6 months and 12 months,
2, 3, and 5 years. DAPT was mandatory for 6 months and recommended up to 12
months.
Results: MACE rates at 12 months were similar in all 3 patients groups: STEMI
(3.9%), NSTEMI (4.7%) and SIHD (4.2%) p¼NS. The rates of deﬁnite stent
thrombosis (ST) were also low in all 3 groups: STEMI (1.0%), NSTEMI (0.4%),
SIHD (0.4%) (STEMI vs. SIHD (p¼0.046), all other pairwise comparisons were NS).
The complete analysis of the outcomes is ongoing.
Conclusions: The use of Biolimus A9-eluting stents is safe and efﬁcient in STEMI,
NSTEMI and SIHD patients at 12-months follow-up. The complete analysis will be
reported for the ﬁrst time during this presentation.
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Background: The impact of left anterior descending artery (LAD) length on left
ventricular (LV) remodeling in pts with anterior ST-elevation myocardial infarction
(STEMI) has not been fully investigated.
Methods: INFUSE-AMI was an open-label, 22 factorial, randomized, multicenter,
single-blind evaluation of bolus intralesion abciximab and manual aspiration
thrombectomy in pts undergoing bivalirudin supported primary PCI for anterior
STEMI. Among 452 enrolled pts, 372 pts with available cardiac magnetic resonance
imaging (cMRI) at 30 days were categorized based on coronary angiography as
having an LAD that supplied inferior wall myocardium vs. an LAD that terminated atB86 JACC Vol 62/18/Suppl B j October 2or before the apex. Major adverse cardiac and heart failure events (MACHFE) were
death, reinfarction, new onset severe heart failure, or rehospitalisation for heart
failure.
Results: Because of poor ﬁnal TIMI ﬂow (0/1) or poor angiography quality, LADs
in 19 pts could not be categorized. Among the remaining 353 pts, 206 (58%) had
an LAD that wrapped around the apex. Although the time from symptom-onset to
ﬁrst device was signiﬁcantly shorter in LADs that wrapped around the apex
and although the frequency of proximal occlusion location and % infarct mass
were similar, LV end diastolic and systolic volumes (assessed by cMRI) at 30 days
were larger than in pts with LADs that terminated before the apex (Table). At 1
year, the rates of MACHFE as well as new onset of severe heart failure and
rehospitalisation for heart failure were signiﬁcantly higher in pts with LADs that
wrapped around the apex compared to pts with LADs that terminated before the
apex.
Conclusions: LAD length is an important determinant of prognosis in pts with
anterior STEMI. In these pts, an LAD that wraps around the apex to supply inferior
wall myocardium is associated with unfavourable LV remodeling and subsequent
heart failure.TCT-264
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Background: Long term prognosis of left ventricular (LV) systolic function was well
known but LV diastolic function in patients with ST segment elevation myocardial
infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI)
was not studied well.
Methods: A consecutive 325 patients treated with primary PCI. Transthoracic
echocardiography was performed within 24 hour after PCI and at 12 months follow-
up. The indices of LV systolic function (LV ejection fraction-EF, wall motion score
index-WMSI), LV diastolic function (The ratio of the transmitral and myocardial early
diastolic velocities (E/Em)) and LV dimension were measured.
Results: At 12 month follow-up, we observed the signiﬁcant improvement of
LVEF (49.19.8 % to 53.910.3 %, p < 0.01), the decrease of WMSI
(1.420.36 to 1.330.37, p < 0.001) and signiﬁcant decrease in LV end diastolic
dimension(52.1  6.6 to 49.86.8). But, there was no signiﬁcant difference but
numerically worsening LV diastolic function (E/Em 12.75.4 to 13.6 7.8,
p¼0.38).
Conclusions: The LV systolic function was improved but LV diastolic function was
not improved after STEMI treated with primary PCI.7–November 1, 2013 j TCT Abstracts/POSTER/STEMI/NSTEMI/ACS
